Major setback at Exelixis as Cometriq fails in prostate cancer
This article was originally published in Scrip
Exelixis has suffered a major setback as its cancer drug Cometriq (cabozantinib) failed to demonstrate overall survival in the Phase III COMET-1 trial in men with metastatic castration-resistant prostate cancer (mCRPC). It has announced a 70% reduction in its workforce following the news.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.